• Explore /
  • Poster
  • / A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

Abstract Poster

Authors

null

Matthew David Hellmann

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Matthew David Hellmann , Toshio Shimizu , Toshihiko Doi , F. Stephen Hodi , Sylvie Rottey , Philippe Georges Aftimos , Zhuqing Tina Liu , Nieves Velez de Mendizabal , Anna M. Szpurka , Yongzhe Piao , Burkhard Vangerow , Leena Gandhi , Ching Ching Leow

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03752177

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2654)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2654

Abstract #

TPS2654

Poster Bd #

293a

Abstract Disclosures

Similar Posters

First Author: Jermaine Coward

First Author: Cai Zhou

First Author: Osama E. Rahma

First Author: Daniel Wilhelm Mueller